Corcept Therapeutics (CORT) Misses Q4 EPS by 5c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $87.59 +0.53%
EPS Growth %: +393.8%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
SFBC, KSBI, PVBK, More
EPS Growth %: +393.8%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
SFBC, KSBI, PVBK, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.20, $0.05 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $202.12 million versus the consensus estimate of $249.52 million.
GUIDANCE:
Corcept Therapeutics sees FY2026 revenue of $0.9-1 billion, versus the consensus of $0.96 billion.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ONEOK (OKE) Tops Q3 EPS by 63c; raises guidance
- Oceanfirst Financial (OCFC) Tops Q3 EPS by 8c
- QNB Corp. (QNBC) Reports Q3 Loss of $1.30
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
